A practical reference on nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Breastmilk may be stored for various amounts of time depending on storage temperature and conditions. The content and quality of expressed milk change over time as it is stored, particularly when frozen. For example, there is a decrease in the ability of breastmilk to kill bacteria when it is stored in the refrigerator for more than 48 hours. Additionally, the quantity of fat, protein, and calories in breastmilk decreases when the milk is frozen for more than 3 months. While several components of breastmilk change over time, inflammatory factors (cytokines) and maternal antibodies, and growth factors are thought to be stable for at least 6 months when the breastmilk is frozen. Storage guidelines, according to the CDC, La Leche League International and the Academy of Breastfeeding Medicine, are noted in the table below.
==== GABA and anesthetics ==== Lots of general anesthetics work by changing how GABA acts in the brain. Drugs such as propofol, etomidate, barbiturates, and many gases like isoflurane and sevoflurane cause GABAa receptors to become more active. When these receptors become more active, GABA open chloride channels for a longer time, which causes nerve cells to be less likely to send signals. GABAa receptors can become desensitized to GABA and stop opening when the ligand is attached. Anesthetics work in two main ways: enhancing the effectiveness of GABA molecules, and manipulating the GABAa receptor to become less susceptible to desensitization. The slowing of brain activity from increased chloride movement causes the body to calm down, become drowsy, and eventually end up in an unconscious state that is needed for surgery. Some anesthetics can even activate GABAa receptors without GABA even being present. The various types of GABA receptors have drug specific reactions which cause the differing effects of anesthetics.
Trading with the Enemy Act of 1917 Foreign Assistance Act of 1961 International Emergency Economic Powers Act of 1977 Export Administration Act of 1979 Several laws specifically prohibit trade with certain countries:
Sources: en.wikipedia.org
In response, the Food Packet, Individual, Combat (FPIC), was developed in the early-1960s, though not fielded until 1966. The FPIC was designed to be nutritious, lightweight, and easily portable, the descendant of the dehydrated rations used by NASA's astronauts. The ration was originally a response to complaints about the weight of the canned ration. Carrying a multi-day supply of heavy wet canned MCI or C-rations, "a special operations team could become virtually immobile due to the weight of needed supplies. Mobility and stealth are decreased when loads become too heavy, and the soldier is too often worn down by midday. Fatigue affects alertness, making him more vulnerable to detection and error." The ration's final 11-ounce (310-gram) weight was a compromise between the original packet's target weight of 5 ounces (140 g) and the base 1-pound (450-gram) target weight of the larger experimental Meal, Ready-to-Eat, Individual (MRE-I), a forerunner of the later MRE. The FPIC differed from the standard wet-pack MCI in that it was a freeze-dried, vacuum-packed individual ration meal weighing 11 ounces (310 g) packed in a waterproof grey-green canvas envelope lined with aluminum foil. Due to its tendency to spoil in wet or humid environments (common in Southeast Asia), later ration packs came enclosed in an outer zip-lock clear-plastic bag to keep out the moisture. This drawback made it less than desirable as a standard ration.
The delegation argued that the annexation was a violation of prior agreements between Moshoeshoe and Wodehouse, while disarmament was unnecessary since the Basuto remained loyal to the Cape. The delegation was not allowed to present its case in the parliament. Petitions from the Basuto and their sympathizers from among the Paris Evangelical Society missionaries followed, all of which failed to produce a favorable result. Letsie I, now old and in declining health, was unwilling to lead an armed revolt, believing it to be futile. Cape Governor Sir Henry Bartle Frere became impatient at the deliberations and ordered Letsie I to enact disarmament immediately, even before the Basuto delegation had returned from Cape Town. Few Basuto complied with the order and handed over their arms. This catalyzed the Cape Parliament to vote in favor of disarmament. The delegation announced their failure to prevent the enactment of the Peace Preservation Act at a pitso convened on 3 July. The heir to the Basuto throne, Lerotholi, spoke against disarmament, while Letsie's brother chief Masopha and his nephew chief Joel Molapo openly challenged the order and advocated for armed resistance. Masopha began to fortify the stronghold of Thaba Bosiu, while the supporters of the rebel chiefs began ignoring orders from the local magistrates. White traders abandoned Basutoland, and Basuto loyalists fled to the magistracies for protection as armed bands roamed freely in the region.
semiconservative replication The standard mode of DNA replication that occurs in all living cells, in which each of the two parental strands of the original double-stranded DNA molecule are used as template strands, with DNA polymerases replicating each strand separately and simultaneously in antiparallel directions. The result is that each of the two double-stranded daughter molecules is composed of one of the original parental strands and one newly synthesized complementary strand, such that each daughter molecule conserves the precise sequence of information (indeed the very same atoms) from one-half of the original molecule. Contrast conservative replication and dispersive replication.
Hypoglycemia due to endogenous insulin Congenital hyperinsulinism Transient neonatal hyperinsulinism (mechanism not known) Focal hyperinsulinism (KATP channel disorders) Paternal SUR1 mutation with clonal loss of heterozygosity of 11p15 Paternal Kir6.2 mutation with clonal loss of heterozygosity of 11p15 Diffuse hyperinsulinism KATP channel disorders SUR1 mutations Kir6.2 mutations Glucokinase gain-of-function mutations Hyperammonemic hyperinsulinism (glutamate dehydrogenase gain-of-function mutations) Short chain acyl coenzyme A dehydrogenase deficiency Carbohydrate-deficient glycoprotein syndrome (Jaeken's Disease) Beckwith-Wiedemann syndrome(suspected due to hyperinsulinism but pathophysiology uncertain: 11p15 mutation or IGF2 excess) Acquired forms of hyperinsulinism Insulinomas (insulin-secreting tumors) Islet cell adenoma or adenomatosis Islet cell carcinoma Adult nesidioblastosis Autoimmune insulin syndrome Noninsulinoma pancreatogenous hypoglycemia Reactive hypoglycemia (also see idiopathic postprandial syndrome) Gastric dumping syndrome Drug induced hyperinsulinism Sulfonylurea Aspirin Pentamidine Quinine Disopyramide Bordetella pertussis vaccine or infection D-chiro-inositol and myo-inositol Hypoglycemia due to exogenous (injected) insulin Insulin self-injected for treatment of diabetes (i.e., diabetic hypoglycemia) Insulin self-injected surreptitiously (e.g., Munchausen syndrome) Insulin self-injected in a suicide attempt or fatality Various forms of diagnostic challenge or "tolerance tests" Insulin tolerance test for pituitary or adrenergic response assessment Protein challenge Leucine challenge Tolbutamide challenge Insulin potentiation therapy Insulin-induced coma for depression treatment
Sources: en.wikipedia.org
== History == Spontaneous CSF leaks have been described by notable physicians and reported in medical journals dating back to the early 1900s. German neurologist Georg Schaltenbrand reported in 1938 and 1953 what he termed "aliquorrhea", a condition marked by very low, unobtainable, or even negative CSF pressures. The symptoms included orthostatic headaches and other features that are now recognized as spontaneous intracranial hypotension. A few decades earlier, the same syndrome had been described in French literature as "hypotension of spinal fluid" and "ventricular collapse". In 1940, Henry Woltman of the Mayo Clinic wrote about "headaches associated with decreased intracranial pressure". The full clinical manifestations of intracranial hypotension and CSF leaks were described in several publications reported between the 1960s and early 1990s. Modern reports of spontaneous CSF leak have been reported to medical journals since the late 1980s.
Wen, LR; Wu, D; Jiang, YM; Prasad, KN; Lin, S; Jiang, GX; He, JR; Zhao, MM; Luo, W; Yang, B (2014). "Identification of flavonoids in litchi (Litchi chinensis Sonn.) leaf and evaluation of anticancer activities". Journal of Functional Foods. 6: 555–563. doi:10.1016/j.jff.2013.11.022.
5 March South Vietnamese Prime Minister, Tran Van Huong, narrowly escaped assassination by a four man VC team as he was being driven to his home in Saigon. Huong's car was attacked by the VC who were wearing stolen Ranger uniforms, however Saigon police and ARVN troops opened fire and gave the driver time to accelerate and escape. The PAVN/VC fired seven rockets into Saigon killing 22 civilians.
== Philanthropy == In April 2017, Metropolis launched a scholarship and mentorship program, called "Medengage", for undergraduate and postgraduate medical students across India. In July 2017, Metropolis and the PCOS Society of India launched a Polycystic Ovarian Syndrome (PCOS) awareness campaign called "Conquer PCOS". In August 2018, Metropolis initiated an "Umbrella Handshake" campaign to create awareness about health. The company donated ₹2 million (equivalent to ₹2.9 million or US$30,000 in 2026) towards this and other social welfare initiatives. Metropolis partnered with We Foundation and Red FM, to help in public outreach and campaign awareness.
Protein biosynthesis or protein synthesis (also known as proteosynthesis) is a core biological process, occurring inside cells, balancing the loss of cellular proteins (via degradation or export) through the production of fresh proteins. Proteins perform a number of critical functions as enzymes, structural proteins or hormones. Protein synthesis is a very similar process for both prokaryotes and eukaryotes but there are some distinct differences. Protein synthesis can be divided broadly into two phases: transcription and translation. During transcription, a section of DNA encoding a protein, known as a gene, is converted into a molecule called messenger RNA (mRNA). This conversion is carried out by enzymes, known as RNA polymerases, in the nucleus of the cell. In eukaryotes, this mRNA is initially produced in a premature form (pre-mRNA) which undergoes post-transcriptional modifications to produce mature mRNA. The mature mRNA is exported from the cell nucleus via nuclear pores to the cytoplasm of the cell for translation to occur. During translation, the mRNA is read by ribosomes which use the nucleotide sequence of the mRNA to determine the sequence of amino acids. The ribosomes catalyze the formation of covalent peptide bonds between the encoded amino acids to form a polypeptide chain. Following translation the polypeptide chain must fold to form a functional protein; for example, to function as an enzyme the polypeptide chain must fold correctly to produce a functional active site.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.